Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 17 July 2015 | By Michael Mezher
In a post to FDA Voice – the US Food and Drug Administration's blog – recently appointed Deputy Commissioner for Medical Products and Tobacco Robert Califf says progress toward curing some diseases, such as Alzheimer's, is being slowed by a lack of understanding of disease biology.
Califf raises this question, and points to some diseases like HIV/AIDS, where advances in scientific understanding have led to "critical insight on how to develop effective treatments." Califf says the discovery of biomarkers, measurable characteristics of the body's response to a disease or treatment, has "resulted in important breakthroughs, rapid drug development and speedy FDA approvals."
The problem, Califf says, is that "the paucity of reliable biomarkers in some diseases highlights the critical need for more research … [For] Alzheimer's and many rare diseases … the scientific community still lacks basic information about what causes these diseases."
Early in the article, Califf calls FDA the world's fastest regulator, and reminds his audience that most new drugs are approved in the US ahead of other markets. So when "viable cures are not in the pipeline," Califf says, pointing the finger at FDA is not the solution.
Califf goes on to say that FDA can help "reduce the length and cost of initial clinical trials for drug approval … by developing tools such as biomarkers and surrogate endpoints." However, while biomarkers and endpoints can help drugmakers target specific mechanisms to treat disease, observational studies are still the gold standard for determining a drug's "cumulative effects."
In a report released alongside Califf's post titled Targeted Drug Development: Why Are Many Diseases Lagging Behind? FDA compares progress in several disease areas, including Alzheimer's, diabetes, rare diseases and hepatitis C (HCV), to scientists' understanding of the causes of those diseases.
For Alzheimer's, FDA points to the fact that, "Scientists have not yet confirmed that any potential biomarkers … [can] predict clinical improvement," except for some rare genetic versions of the disease. Likewise, treatment options for Alzheimer's are poor.
In contrast, drugmakers have made massive leaps in treating HCV, after technologies developed in the 1990s to better understand AIDS were applied to other viral infections, including HCV. These technologies helped scientists better understand HCV and fostered the development of so-called "direct-acting" drugs, such as Gilead Sciences' massively successful Sovaldi and Harvoni.
FDA Voice, Targeted Drug Development: Why Are Many Diseases Lagging Behind?
Tags: Precision Medicine, Biomarkers, Surrogate Endpoints, HCV, Alzheimer's, Robert Califf
Regulatory Focus newsletters
All the biggest regulatory news and happenings.